vimarsana.com

Page 13 - சர்வதேச கூட்டமைப்பு ஆஃப் மருந்து உற்பத்தியாளர்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Support for IP waiver on COVID-19 vaccines gains momentum; snags remain

GENEVA – France joined the United States on Thursday in supporting an easing of patent and other protections on COVID-19vaccines that could help poorer countries get more doses and speed the end of the pandemic. While the backing from two countries with major drug makers is important, many obstacles remain. The move to support waiving intellectual property protections on vaccines under World Trade Organization rules marked a dramatic shift for the United States and drew cheers from activists, complaints from Big Pharma, and a lot of questions about what comes next. Washington had previously lined up with many other developed nations opposed to the idea floated by India and South Africa in October.

Support Grows for Vaccine IP Waiver

About DTN DTN delivers accurate, objective, real-time, and actionable insights to increase our 2 million customers’ confidence and support their business decisions. In a data-rich world, our actionable insights in weather and financial analytics make sense of the information, drive change in processes and help businesses prosper. They empower our agriculture, energy and transportation customers – those who work endlessly to feed, fuel and protect our world. We believe that when our customers are supported with the most reliable and innovative information to the Nth Degree, they prosper and we all win. DTN is based in Minneapolis with offices globally.

WRAPUP 1-EU ready to discuss COVID vaccine patent waiver as drugmakers push back

WRAPUP 3-EU supports COVID vaccine patent waiver talks, but critics say won t solve scarcity Reuters 7 hrs ago (Adds U.S. secretary of state, analyst comment, details on shortcomings of plan; updates shares) U.S. says waiver would increase vaccine manufacturing Critics say patent restrictions not responsible for scarcity Drugmaker stocks mostly recover after sharp drop By Philip Blenkinsop and Carl O Donnell BRUSSELS/NEW YORK, May 6 (Reuters) - The European Union on Thursday backed a U.S. proposal to discuss waiving patent protections for COVID-19 vaccines, but drugmakers and some other governments opposed the idea, saying it would not solve global inoculation shortages.

EU ready to discuss waiver on Covid vaccine patents

EU ‘ready to discuss’ waiver on Covid vaccine patents Patrick Wintour Diplomatic editor © Provided by The Guardian Photograph: Yves Herman/EPA The head of the European Commission, Ursula von der Leyen, has said the bloc is “ready to discuss” a US-backed proposal for a waiver on the patents for Covid-19 vaccines and the French president, Emmanuel Macron, said he was “absolutely in favour” of the plan as pressure built for a move that could boost their production and distribution around the world. Pharmaceutical companies reacted with anger, and some countries with private astonishment, at the Joe Biden administration’s decision on Wednesday to back the temporary suspension of vaccine patent rights. One diplomat accused the US of grandstanding and coming up with crowd-pleasing simplistic solutions to long-term problems.

Thu 8:35 a m : Support grows for IP waiver on virus vaccines; snags remain | News, Sports, Jobs

May 6, 2021 In this April 8 file photo, a Northwell Health registered nurses fills a syringe with the Johnson & Johnson COVID-19 vaccine at a pop up vaccination site at the Albanian Islamic Cultural Center in the Staten Island borough of New York. The Biden administration on Wednesday joined calls for more sharing of the technology behind COVID-19 vaccines to help speed the end of the pandemic, a shift that puts the U.S. alongside many in the developing world who want rich countries to do more to get doses to the needy. (AP Photo/Mary Altaffer, File) GENEVA (AP) France joined the United States today in supporting an easing of patent and other protections on COVID-19 vaccines that could help poorer countries get more doses and speed the end of the pandemic. While the backing from two countries with major drug makers is important, many obstacles remain.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.